Publications by authors named "Veronique Keppenne"

Claim this Profile
C
Clean intermittent catheterization in multiple sclerosis patients: An adherence and long-term follow-up study.
Bérengère Maillard, Hélena Cassol, Justine Slomian, Stephen Bornheim, Jean-François Kaux, Véronique Keppenne

Fr J Urol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent catheterisation: individuals' rights, accessibility, and environmental concerns.
Andrei Krassioukov, Michel Wyndaele, Matthias Walter, Veronique Keppenne, Blayne Welk

Spinal Cord Ser Cases· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The overactive bladder syndrome].
Thomas Verjans, Manon Dewandre, Véronique Keppenne, Julie Leruth, David Waltregny

Rev Med Liege· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent catheterization: A patient-centric approach is key to optimal management of neurogenic lower urinary tract dysfunction.
Andrei Krassioukov, Blayne Welk, Desiree Vrijens, Sabrina Islamoska, Kim Bundvig Barken, Veronique Keppenne

Front Urol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
Mark Tullman, Emmanuel Chartier-Kastler, Alfred Kohan, Veronique Keppenne, Benjamin M Brucker

Neurology· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
David Ginsberg, Francisco Cruz, Sender Herschorn, Angelo Gousse, Véronique Keppenne

Adv Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
David Ginsberg, Angelo Gousse, Veronique Keppenne, Karl-Dietrich Sievert, Catherine Thompson

J Urol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis